Sintx Technologies initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Sintx Technologies (SINT) with a Buy rating and $10 price target Sintx is developing silicon nitride-based biomaterials, which offer a “differentiated combination” of antimicrobial properties and bone integration that can disrupt traditional orthopedic implant materials, the analyst tells investors in a research note. The firm sees the company entering a “more relevant” commercial phase, supported by expanding applications and growing external validation.